Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol

Table 1 Therapeutic regimen

Regimen	Dose	Course of treatment	Treatment modalities	Administration time
AS group
Paclitaxel (albumin-bound)	120 mg/m²	Q3W	IV	D1, 8
S-1	< 1.25 m², 40 mg; 1.25m² to < 1.5 m², 50 mg; and > 1.5 m², 60 mg	Q3W	Oral	D1–14
XELOX group
Oxaliplatin	130 mg/m²	Q3W	IV	D1
Capecitabine	1000 mg/m²	Q3W	Oral	D1–14

ISSN: 1471-2407